Clinical Trial Update: Expanded Access to Ziftomenib

View source ↗

Summary

Kura Oncology announces expanded access to the investigational menin inhibitor ziftomenib for eligible patients with acute lymphoblastic leukemia and acute myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia with Npm1 Mutations

Drugs mentioned

• Ziftomenib (ziftomenib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations | Status: AVAILABLE